Research Topics
| H S CuckleSummaryAffiliation: University of Leeds Country: UK Publications
| Collaborators
|
Detail Information
Publications
Nuchal translucency screening in triplets: Down syndrome risk calculation taking account of between-fetus correlationsHoward Cuckle
Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA
Prenat Diagn 32:214-9. 2012..To describe a method for calculating fetus-specific Down syndrome risk in triplets, allowing for nuchal translucency (NT) correlation between fetuses...
Age-standardisation when target setting and auditing performance of Down syndrome screening programmesHoward Cuckle
Reproductive Epidemiology, University of Leeds, UK
Prenat Diagn 24:851-6. 2004..To describe and illustrate a method of setting Down syndrome screening targets and auditing performance that allows for differences in the maternal age distribution...- Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parametersHoward Cuckle
University of Leeds, Leeds, UK
Semin Perinatol 29:252-7. 2005..To predict the screening performance for 17 policies currently in use or being considered for the near future... - Suboptimal Down syndrome screening test interpretationH Cuckle
Leeds Screening Centre, University of Leeds Leeds LS7 3JB, UK
Ultrasound Obstet Gynecol 27:6-8. 2006 - Screening for pre-eclampsia--lessons from aneuploidy screeningH S Cuckle
Department of Obsterics and Gynecology, Columbia University Medical Center, 622 W 168th Street, PH1666, New York, NY 10032, USA
Placenta 32:S42-8. 2011..Antenatal screening for aneuploidy is an established routine clinical practice worldwide. The same statistical methodology, developed and refined over three decades, might be adapted to screening for pre-eclampsia... - Biochemical screening for Down syndromeH Cuckle
Reproductive Epidemiology, Centre for Reproduction, Growth and Development, School of Medicine, University of Leeds, 26 Clarendon Road, LS2 9NZ, Leeds, UK
Eur J Obstet Gynecol Reprod Biol 92:97-101. 2000..Abnormal marker levels are also associated with a variety of adverse outcomes of pregnancy. High quality information and decision aids are needed to minimise anxiety among screenees... - Maternal urine hyperglycosylated hCG in pregnancies with Down syndromeH S Cuckle
Centre for Reproduction, Growth and Development, University of Leeds, U K
Prenat Diagn 19:918-20. 1999..34 multiples of the normal median (MoM). The H-hCG elevation in affected pregnancies was more marked at 14 weeks' gestation or later: a median of 4.64 MoM and allowing for creatinine bias 4.46 MoM... - Collaborative study of maternal urine beta -core human chorionic gonadotrophin screening for Down syndromeH S Cuckle
Reproductive Epidemiology, Centre for Reproduction, Growth and Development, University of Leeds, U K
Prenat Diagn 19:911-7. 1999..But the considerable variability in results between studies means that further research is needed before a reliable conclusion can be drawn... - Maternal serum activin A and follistatin levels in pregnancies with Down syndromeH S Cuckle
Centre for Reproduction, Growth and Development, University of Leeds, UK
Prenat Diagn 19:513-6. 1999..However, the extent of overlap was too great to be of value in screening. There was a small decrease in follistatin levels among cases but it did not reach statistical significance... - Appropriate biochemical parameters in first-trimester screening for Down syndromeH S Cuckle
Centre for Reproduction, Growth and Development, School of Medicine, University of Leeds, UK
Prenat Diagn 19:505-12. 1999..1 per cent. Routine ultrasound nuchal translucency measurement in addition to serum testing will increase the rates to 86.4 per cent, 87.2 per cent, 87.9 per cent and 88.3 per cent, respectively... - The effect of smoking in pregnancy on maternal serum inhibin A levelsE L Ferriman
Department of Feto Maternal Medicine, Leeds General Infirmary, UK
Prenat Diagn 19:372-4. 1999..The increase was highly statistically significant (p<0.0001, Wilcoxon rank sum test, two-tail). On the basis of these results we conclude that if inhibin A is used as a marker, adjustment for maternal smoking status may be necessary... - Effect of maternal age curve on the predicted detection rate in maternal serum screening for Down syndromeH S Cuckle
Centre for Reproduction, Growth and Development, School of Medicine, University of Leeds, U K
Prenat Diagn 18:1127-30. 1998..1-6.5 per cent for inhibin A. This analysis shows that the model inaccuracy caused by the maternal age curve is not small but is unlikely to be large enough to influence Down syndrome screening policy decisions... - Down syndrome screening marker levels in women with a previous aneuploidy pregnancyHoward S Cuckle
Reproductive Epidemiology, University of Leeds, Leeds, UK
Prenat Diagn 25:47-50. 2005..In Down syndrome screening programmes, women with a previous affected pregnancy are assumed to have the same marker distribution as those without a family history. This assumption needs to be tested... - Nomograms to help inform women considering Down's syndrome screeningH S Cuckle
Centre for Reproduction, Growth and Development, Research School of Medicine, Leeds, UK
Eur J Obstet Gynecol Reprod Biol 69:69-72. 1996..To derive graphical information for use in counselling women considering whether or not to have maternal serum screening for Down's syndrome... - Compromise ultrasound dating policy in maternal serum screening for Down syndromeR R Rahim
Reproductive Epidemiology, University of Leeds, Leeds, UK
Prenat Diagn 22:1181-4. 2002..06-0.6% and 0.0-0.3%, respectively. We conclude that if routine ultrasound is not financially and practically feasible, the compromise policy yields a clinically important improvement in screening performance compared to menstrual dating... - Decisions about testing and termination of pregnancy for different fetal conditions: a qualitative study of European White and Pakistani mothers of affected childrenShenaz Ahmed
Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
J Genet Couns 17:560-72. 2008..The findings also challenge stereotypes about cultural differences in attitudes about termination of pregnancy... - Attitudes to prenatal testing and termination of pregnancy for fetal abnormality: a comparison of white and Pakistani women in the UKJenny Hewison
Professor of the Psychology of Healthcare, Institute of Health Sciences and Public Health Research, University of Leeds School of Medicine, 15 Hyde Terrace, Leeds LS2 9LT, UK
Prenat Diagn 27:419-30. 2007.... - Contingent screening for Down syndrome--results from the FaSTER trialHoward S Cuckle
Columbia University, New York, USA
Prenat Diagn 28:89-94. 2008..Comparison of contingent, step-wise and integrated screening policies... - Aneuploidy screening: what test should I use?Richard L Berkowitz
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York 10128, USA
Obstet Gynecol 107:715-8. 2006..In this commentary we will define and discuss both the advantages and disadvantages of using integrated, stepwise, sequential or contingency screening for risk assessment of fetal aneuploidy... - Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic reviewJ M Green
Mother and Infant Research Unit, University of Leeds, UK
Health Technol Assess 8:iii, ix-x, 1-109. 2004.... - Serum müllerian-inhibiting substance in Down's syndrome pregnanciesDavid B Seifer
Maimonides Medical Center, Brooklyn, New York, NY, USA
Hum Reprod 22:1017-20. 2007..To examine whether maternal serum levels of müllerian-inhibiting substance (MIS) differ in Down's syndrome and unaffected pregnancies... - First- and second-trimester screening: detection of aneuploidies other than Down syndromeFionnuala M Breathnach
Royal College of Surgeons in Ireland
Obstet Gynecol 110:651-7. 2007..To evaluate the performance of first- and second-trimester screening methods for the detection of aneuploidies other than Down syndrome... 
First-trimester maternal serum PP13 in the risk assessment for preeclampsiaRoberto Romero
Department of Health and Human Services, Perinatology Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
Am J Obstet Gynecol 199:122.e1-122.e11. 2008..The objective of the study was to determine whether first-trimester maternal serum placental protein 13 (PP13) concentrations can be used in the risk assessment for preeclampsia...- Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markersLorraine Dugoff
Department of Obstetrics and Gynecology, University of Colorado at Denver Health Sciences Center, Aurora, CO, USA
Am J Obstet Gynecol 199:290.e1-6. 2008..To develop and evaluate a method of estimating patient-specific risk for fetal loss by combining maternal characteristics with serum markers... - Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?Kevin Spencer
Clinical Biochemistry Department, Harold Wood Hospital, Gubbins Lane, Romford, Essex RM3 0BE, UK
Prenat Diagn 22:903-6. 2002..To evaluate whether repeat sampling and testing of free beta-hCG and PAPP-A during this period would result in an improved detection rate... - Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery DopplerAris T Papageorghiou
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, London, UK
BJOG 112:703-9. 2005..1% and with combined assessment it was 67.5%. CONCLUSIONS: Combining risk factors in the mother's history with Doppler of the uterine arteries allows calculation of patient-specific risk for the development of pre-eclampsia...